Cardio3 BioSciences, an international Mayo Clinic collaborator, has received FDA approval for a phase III pivotal clinical trial of its stem cell therapy. The trial will test the Mayo Clinic discovery of cardiopoietic (cardiogenically-instructed) stem cells designed to improve heart health in people suffering from heart failure. The multisite U.S. trial, called CHART-2, will aim to recruit 240 patients with chronic advanced symptomatic heart failure. Cardio3 BioSciences is a biotechnology company in Mont-Saint-Guibert, Belgium.

"Regenerative medicine is poised to transform the way we treat patients," says Andre Terzic, M.D., Ph.D., director of the Mayo Clinic Center for Regenerative Medicine. Watch the video below to see how stem cells are being used to treat people with heart failure.
http://youtu.be/vumB_FW_fTA

Tags: Andre Terzic, Atta Behfar, cardiac regeneration, Cardio3 Biosciences, European stem cell trial, heart disease, Mayo Clinic, News, regenerative medicine, Research, stem cells